Welcome to LookChem.com Sign In|Join Free
  • or
N-phenyl-N-(4-piperidinyl)butanamide is a chemical compound with the molecular formula C18H26N2O. It is a white crystalline solid that belongs to the class of amides, specifically a substituted butanamide. N-phenyl-N-(4-piperidinyl)butanamide features a phenyl group (C6H5) attached to the nitrogen atom, which is also connected to a 4-piperidinyl group (a piperidine ring with a substituent at the 4-position). The butanamide part of the molecule consists of a butane chain with an amide group (-CONH2) at the end. N-phenyl-N-(4-piperidinyl)butanamide is known for its potential applications in the pharmaceutical industry, particularly as a precursor in the synthesis of various drugs and medicinal compounds. Its chemical structure and properties make it a versatile building block for the development of new therapeutic agents.

1432-03-7

1432-03-7 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.

1432-03-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1432-03-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,3 and 2 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1432-03:
(6*1)+(5*4)+(4*3)+(3*2)+(2*0)+(1*3)=47
47 % 10 = 7
So 1432-03-7 is a valid CAS Registry Number.

1432-03-7Relevant academic research and scientific papers

Pharmacological profile of a novel series of NK1, antagonists. In vitro and in vivo potency of benzimidazolone derivatives

Remond,Portevin,Bonnet,Canet,Regoli,De Nanteuil

, p. 843 - 868 (2007/10/03)

By low throughput examination of our chemical library, compound 7 was selected as a lead NK1, antagonist with a K(i) of 7.1 nM. Modifications of its structure led to the finding that the in vitro potency could be markedly enhanced by disubstituting the anilino phenyl ring as in compounds 13 or 22. Human binding data correlated rather well with results obtained with in vitro animal smooth muscle preparations. Several agents proved to possess antinociceptive properties as exemplified in the hot-plate test in mice; compound 13 was the most active with ED50 of 0.001 and 0.3 mg/kg after iv and po administration respectively. Furthermore, antagonist 71 was found to be a potent inhibitor of SP-induced bronchoconstriction in guinea-pigs with an ED50 between 0.1 and 0.03 mg/kg iv. Furthermore, upon oral administration, 71 was observed to be active in a model of SP-induced bronchial hypersensitivity in mice, with an ID50 of around 3 mg/kg.